Fairvalue-Calculator Fairvalue-Calculator
EN DE

TaiGen Biopharmaceuticals Holdings (4157) Fair Value & Analysis

Healthcare · TW · Market cap 6.3B TWD

Price8.46 TWD
Fair Value1.51 TWD
Upside-82.2%
Quality95/100
Evidence: High Range 1.10 TWD – 1.84 TWD

Fair value as of: Jun 24, 2026

✦ Find undervalued quality stocks — 34,000+ analysed Find stocks →

Analysis

TaiGen Biopharmaceuticals Holdings (4157) currently trades at 8.46 TWD, while our model-based Fair Value estimate is 1.51 TWD — implying the stock looks roughly 82.2% overvalued today. We read business quality at 95/100 (high quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: high).

About the company

TaiGen Biopharmaceuticals Holdings Limited, a pharmaceutical company, develops novel therapeutics for transformative diseases worldwide. The company develops Taigexyn (Nemonoxacin), a non-fluorinated quinolone antibiotic for the treatment of bacterial infections. Its product pipeline comprises Taigexyn, which is in phase II clinical trial for the treatment of community-acquired pneumonia/diabetic foot infection; TG-1000, which is in phase III clinical trial to treat influenza A and B; TG-4318; ISM-4808 to treat CKD anemia; Furaprevir, a HCV protease inhibitor for the treatment of chronic hepatitis C; and Burixafor, a stem cell mobilizer which is in phase II clinical trial for stem cell transplantation and chemosenzitization. In addition, the company is involved in the provision of consultation on pharmaceutical technology; and manufacture and sale of health food. The company was founded in 2001 and is based in Taipei City, Taiwan.

Open the full interactive analysis →

Similar stocks

Vertex Pharmaceuticals Incorporated (VRTX34) -38% Regeneron Pharmaceuticals, Inc (REGN) -14% UCB SA (UCB) -27% argenx SE (ARGNF) -57% Samsung Biologics Co (207940) -28% Alnylam Pharmaceuticals, Inc (ALNY) -63%

Frequently asked questions

Is TaiGen Biopharmaceuticals Holdings (4157) undervalued?
As of Jun 24, 2026, our model estimates a fair value of 1.51 TWD versus a price of 8.46 TWD — about −82% (overvalued). Model-based estimate, not financial advice.
What is the fair value of 4157?
Our 21-model fair value for TaiGen Biopharmaceuticals Holdings is 1.51 TWD (as of Jun 24, 2026), built from audited fundamentals. The current price is 8.46 TWD.
What is the quality score of 4157?
TaiGen Biopharmaceuticals Holdings has a Quality Score of 95/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.